Corvidia Therapeutics’ $60 Million Series B Financing Round

Ambrogio Visconti

Goodwin advised Corvidia Therapeutics on the deal Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, closed a $60 million USD Series B funding round. The…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here